Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trans sodium crocetinate - CervoMed

Next Previous
X
Search
Drug Profile

Trans sodium crocetinate - CervoMed

Alternative Names: Crocetin sodium salt; Sodium crocetinate; Trans sodium crocetinate; Transcrocetinate sodium; TSC; TSC-cpd

Latest Information Update: 28 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Office of Naval Research; University of Virginia
  • Developer CervoMed; Diffusion Pharmaceuticals; University of Virginia
  • Class Antineoplastics; Carotenoids; Dicarboxylic acids; Neuroprotectants; Radiation-sensitising agents; Small molecules; Vascular disorder therapies
  • Mechanism of Action Oxygen compound modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain metastases; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioblastoma

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II Interstitial lung diseases; Stroke
  • Phase I/II COVID 2019 infections; SARS-CoV-2 acute respiratory disease
  • No development reported Brain metastases; Hypoxia; Pancreatic cancer
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Brain metastases in USA (IV, Injection)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Hypoxia(In volunteers) in USA (IV)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer in USA (IV, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top